Neuroinflammation Biomarkers in the AT(N) Framework Across the Alzheimer's Disease Continuum
Open accessThe DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Abstract
In the past years, neuroinflammation has been widely investigated in Alzheimer's disease (AD). Evidence from animal, in vivo and post-mortem studies has shown that inflammatory changes are a common feature of the disease, apparently happening in response to amyloid-beta and tau accumulation. Progress in imaging and fluid biomarkers now allows for identifying surrogate markers of neuroinflammation in living individuals, which may offer unprecedented opportunities to better understand AD pathogenesis and progression. In this context, inflammatory mediators and glial proteins (mainly derived from microglial cells and astrocytes) seem to be the most promising biomarkers. Here, we discuss the biological basis of neuroinflammation in AD, revise the proposed neuroinflammation biomarkers, describe what we have learned from anti-inflammatory drug trials, and critically discuss the potential addition of these biomarkers in the AT(N) framework.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Neurotoxic reactive astrocytes are induced by activated microglia
Liddelow, S. A., Guttenplan, K. A., Clarke, L. E., Bennett, F. C., Bohlen, C. J., Schirmer, L., Bennett, M. L., Münch, A. E., Chung, W.-S., Peterson, T. C., et al. (2017) · Nature · doi:10.1038/nature21029 · Cited by 7,971
Inflammaging: a new immune–metabolic viewpoint for age-related diseases
Franceschi, C., Garagnani, P., Parini, P., Giuliani, C., & Santoro, A. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0059-4 · Cited by 3,586 · cited 1×
“Another important hypothesis in the genesis of neurodegenerative diseases is inflammaging (34).”
BackgroundNeuroinflammation and microglial activation in Alzheimer disease: where do we go from here?
Leng, F., & Edison, P. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-020-00435-y · Cited by 3,179 · cited 2×
“A possible explanation for previous failures is that antiinflammatory drugs impact both protective and harmful inflammatory states of glial cells (20).”
BackgroundNeuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes
Kwon, H. S., & Koh, S.-H. (2020) · Translational Neurodegeneration · doi:10.1186/s40035-020-00221-2 · Cited by 2,595
Reactive astrocyte nomenclature, definitions, and future directions
Escartin, C., Galea, E., Lakatos, A., O’Callaghan, J. P., Petzold, G. C., Serrano-Pozo, A., Steinhäuser, C., Volterra, A., Carmignoto, G., Agarwal, A., et al. (2021) · Nature Neuroscience · doi:10.1038/s41593-020-00783-4 · Cited by 2,513 · cited 2×
“While reactive astrocytes were initially considered a homogeneous population, nowadays, there is a consensus that astrocytes assume multiple phenotypes in response to different pathological stimuli (26, 28).”
BackgroundSelf-citationAzevedo, F. A. C., Carvalho, L. R. B., Grinberg, L. T., Farfel, J. M., Ferretti, R. E. L., Leite, R. E. P., Filho, W. J., Lent, R., & Herculano‐Houzel, S. (2009) · Journal of Comparative Neurology · doi:10.1002/cne.21974 · Cited by 2,337 · cited 1×
“Reactive astrogliosis refers to molecular, functional, and morphological changes that may impact the brain environment during pathological stimuli, such as hypoxia, cytokines, misfolded proteins, low glucose supply, neurotransmitter imbalance, and ROS (23-26).”
BackgroundImmune attack: the role of inflammation in Alzheimer disease
Heppner, F. L., Ransohoff, R. M., & Becher, B. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn3880 · Cited by 2,134 · cited 1×
“As for the brain, it is important to differentiate the adaptive immune response, a core feature of multiple sclerosis and autoimmune encephalitis, from the innate immune response, mostly as seen in neurodegenerative diseases (15).”
BackgroundMicroglia states and nomenclature: A field at its crossroads
Paolicelli, R. C., Sierra, A., Stevens, B., Tremblay, M.-E., Aguzzi, A., Ajami, B., Amit, I., Audinat, E., Bechmann, I., Bennett, M., et al. (2022) · Neuron · doi:10.1016/j.neuron.2022.10.020 · Cited by 1,973
Neuroinflammation in Alzheimer's disease: current evidence and future directions
Calsolaro, V., & Edison, P. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.02.010 · Cited by 1,726 · cited 1×
“It is proposed that repeated exposure to hazardous stimuli might cause microglia to become aberrantly active, sustaining noxious conditions to the CNS and, eventually, leading to, or accelerating, neurodegeneration (20, 21).”
BackgroundAn Overview of Oxidative Stress, Neuroinflammation, and Neurodegenerative Diseases
Teleanu, D. M., Niculescu, A.-G., Lungu, I. I., Radu, C. I., Vladâcenco, O., Roza, E., Costăchescu, B., Grumezescu, A. M., & Teleanu, R. I. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23115938 · Cited by 1,085 · cited 1×
“In the specific context of AD, along with mitochondrial production of ROS, there is evidence that Aβ plaques may also be a source of ROS production (186, 187).”
BackgroundMicroglia in Alzheimer's disease
Sarlus, H., & Heneka, M. T. (2017) · Journal of Clinical Investigation · doi:10.1172/jci90606 · Cited by 911
Lee, J. W., Lee, Y. K., Yuk, D. Y., Choi, D. Y., Ban, S. B., Oh, K. W., & Hong, J. T. (2008) · Journal of Neuroinflammation · doi:10.1186/1742-2094-5-37 · Cited by 772
Minocycline selectively inhibits M1 polarization of microglia
Kobayashi, K., Imagama, S., Ohgomori, T., Hirano, K., Uchimura, K., Sakamoto, K., Hirakawa, A., Takeuchi, H., Suzumura, A., Ishiguro, N., et al. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.54 · Cited by 742
Clinical trials of new drugs for Alzheimer disease
Huang, L.-K., Chao, S.-P., & Hu, C.-J. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-019-0609-7 · Cited by 702 · cited 1×
“In AD, prognostic biomarkers have promising clinical applications because drug therapies are supposed to start before symptoms (192).”
BackgroundRevisiting the Mechanisms of CNS Immune Privilege
Louveau, A., Harris, T. H., & Kipnis, J. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.08.006 · Cited by 682 · cited 1×
“The absence of signs of inflammation in diseases of the central nervous system (CNS) was historically behind the dogma of the brain as an “immune-privileged” organ (12, 13).”
BackgroundFunction and therapeutic value of astrocytes in neurological diseases
Lee, H.-G., Wheeler, M. A., & Quintana, F. J. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00390-x · Cited by 662
Benedet, A. L., Milà-Alomà, M., Vrillon, A., Ashton, N. J., Pascoal, T. A., Lussier, F., Karikari, T. K., Hourregue, C., Cognat, E., Dumurgier, J., et al. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2021.3671 · Cited by 638 · cited 9×
“However, an association was observed between CSF GFAP and Aβ pathology in CU individuals, as assessed by PET and CSF biomarkers (62, 63).”
BackgroundInfluentialSelf-citationPlasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer's disease
Pereira, J. B., Janelidze, S., Smith, R., Mattsson-Carlgren, N., Palmqvist, S., Teunissen, C. E., Zetterberg, H., Stomrud, E., Ashton, N. J., Blennow, K., et al. (2021) · Brain · doi:10.1093/brain/awab223 · Cited by 598
Maphis, N., Xu, G., Kokiko-Cochran, O. N., Jiang, S., Cardona, A., Ransohoff, R. M., Lamb, B. T., & Bhaskar, K. (2015) · Brain · doi:10.1093/brain/awv081 · Cited by 595 · cited 1×
“It is thought that inflammatory changes are a response to Aβ and tau pathologies, but one cannot rule out that they are triggering the deposition of Aβ and tau in the brain (6-8).”
BackgroundChételat, G., Arbizu, J., Barthel, H., Garibotto, V., Law, I., Morbelli, S., van de Giessen, E., Agosta, F., Barkhof, F., Brooks, D. J., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30314-8 · Cited by 526
YKL-40: A Novel Prognostic Fluid Biomarker for Preclinical Alzheimer's Disease
Craig-Schapiro, R., Perrin, R. J., Roe, C. M., Xiong, C., Carter, D., Cairns, N. J., Mintun, M. A., Peskind, E. R., Li, G., Galasko, D. R., et al. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.08.025 · Cited by 504 · cited 2×
“Indeed, studies observed only a modest correlation between CSF and plasma YKL40 levels (94, 95).”
BackgroundMicroglial activation and tau propagate jointly across Braak stages
Pascoal, T. A., Benedet, A. L., Ashton, N. J., Kang, M. S., Therriault, J., Chamoun, M., Savard, M., Lussier, F. Z., Tissot, C., Karikari, T. K., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01456-w · Cited by 490
Self-citationReactive Glia not only Associates with Plaques but also Parallels Tangles in Alzheimer’s Disease
Serrano-Pozo, A., Mielke, M. L., Gómez-Isla, T., Betensky, R. A., Growdon, J. H., Frosch, M. P., & Hyman, B. T. (2011) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.05.047 · Cited by 488 · cited 1×
“Reactive astrocytes have been reported in numerous diseases and are typically observed in post-mortem AD brains, colocalizing with Aβ and tau pathologies (27).”
BackgroundThe contribution of neuroinflammation to amyloid toxicity in Alzheimer's disease
Minter, M. R., Taylor, J. M., & Crack, P. J. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13411 · Cited by 451
Brosseron, F., Krauthausen, M., Kummer, M., & Heneka, M. T. (2014) · Molecular Neurobiology · doi:10.1007/s12035-014-8657-1 · Cited by 447
Carter, S. F., Schöll, M., Almkvist, O., Wall, A., Engler, H., Långström, B., & Nordberg, A. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.110.087031 · Cited by 442 · cited 1×
“A peak in [11C]DED binding was observed in MCI Aβ-positive patients (141) and presymptomatic autosomal dominant Alzheimer’s disease (ADAD) mutation carriers (142).”
BackgroundChatterjee, P., Pedrini, S., Stoops, E., Goozee, K., Villemagne, V. L., Asih, P. R., Verberk, I. M. W., Dave, P., Taddei, K., Sohrabi, H. R., et al. (2021) · Translational Psychiatry · doi:10.1038/s41398-020-01137-1 · Cited by 439
Peripheral and central immune system crosstalk in Alzheimer disease — a research prospectus
Bettcher, B. M., Tansey, M. G., Dorothée, G., & Heneka, M. T. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00549-x · Cited by 427 · cited 1×
“Clinical evidence suggests that innate and adaptive immnune responses occur in AD and seem dependent on the disease stage (17).”
BackgroundZhong, L., Xu, Y., Zhuo, R., Wang, T., Wang, K., Huang, R., Wang, D., Gao, Y., Zhu, Y., Sheng, X., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09118-9 · Cited by 371 · cited 1×
“The activation of TREM2 in animal models has produced controversial results, either ameliorating pathological phenotypes (38) or exacerbating AD pathology’s spreading (39).”
ResultGold, M., Alderton, C., Zvartau-Hind, M., Egginton, S., Saunders, A. M., Irizarry, M., Craft, S., Landreth, G., Linnamägi, Ü., & Sawchak, S. (2010) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000318845 · Cited by 361
Palmqvist, S., Insel, P. S., Stomrud, E., Janelidze, S., Zetterberg, H., Brix, B., Eichenlaub, U., Dage, J. L., Chai, X., Blennow, K., et al. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201911170 · Cited by 353
Initiative, F. T. A. D. N., Suárez-Calvet, M., Morenas-Rodríguez, E., Kleinberger, G., Schlepckow, K., Araque Caballero, M. Á., Franzmeier, N., Capell, A., Fellerer, K., Nuscher, B., et al. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0301-5 · Cited by 347 · cited 2×
“Specifically, CSF sTREM2 levels decrease in response to CSF Aβ1-42 (49, 50) but increase in response to CSF tau elevation (total tau or phosphorylated tau) (50), suggesting it is a stagespecific biomarker.”
Background[18F]FDG PET signal is driven by astroglial glutamate transport
Zimmer, E. R., Parent, M. J., Souza, D. G., Leuzy, A., Lecrux, C., Kim, H.-I., Gauthier, S., Pellerin, L., Hamel, E., & Rosa-Neto, P. (2017) · Nature Neuroscience · doi:10.1038/nn.4492 · Cited by 343 · cited 1×
“For instance, [18F]FDG-PET is sensitive to activation/deactivation of astrocytes and microglial cells (171-175).”
MethodSelf-citationEnhancing protective microglial activities with a dual function TREM2 antibody to the stalk region
Schlepckow, K., Monroe, K. M., Kleinberger, G., Cantuti‐Castelvetri, L., Parhizkar, S., Xia, D., Willem, M., Werner, G., Pettkus, N., Brunner, B., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.201911227 · Cited by 324 · cited 1×
“An increase in sTREM2 proteolytic shedding seems directly related to decreased TREM2 activity (37).”
BackgroundThe dual roles of cytokines in Alzheimer’s disease: update on interleukins, TNF-α, TGF-β and IFN-γ
Zheng, C., Zhou, X.-W., & Wang, J.-Z. (2016) · Translational Neurodegeneration · doi:10.1186/s40035-016-0054-4 · Cited by 292
Glial activation and inflammation along the Alzheimer’s disease continuum
Nordengen, K., Kirsebom, B.-E., Henjum, K., Selnes, P., Gísladóttir, B., Wettergreen, M., Torsetnes, S. B., Grøntvedt, G. R., Waterloo, K. K., Aarsland, D., et al. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1399-2 · Cited by 274 · cited 1×
“While some studies observed increased significant differences between cognitively unimpaired (CU) and AD dementia individuals’ (40, 41) other reports found no alterations (42-48).”
ResultMicroglial activation correlates in vivo with both tau and amyloid in Alzheimer’s disease
Dani, M., Wood, M., Mizoguchi, R., Fan, Z., Walker, Z., Morgan, R., Hinz, R., Biju, M., Kuruvilla, T., Brooks, D. J., et al. (2018) · Brain · doi:10.1093/brain/awy188 · Cited by 270 · cited 1×
“However, in a similar study (115), AD patients displayed displayed a trend for increased uptake in some brain regions, but they were not significant.”
ResultXiang, X., Wind, K., Wiedemann, T., Blume, T., Shi, Y., Briel, N., Beyer, L., Biechele, G., Eckenweber, F., Zatcepin, A., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abe5640 · Cited by 268 · cited 1×
“For instance, [18F]FDG-PET is sensitive to activation/deactivation of astrocytes and microglial cells (171-175).”
MethodBrain borders at the central stage of neuroimmunology
Rustenhoven, J., & Kipnis, J. (2022) · Nature · doi:10.1038/s41586-022-05474-7 · Cited by 253
Milà‐Alomà, M., Salvadó, G., Gispert, J. D., Vilor‐Tejedor, N., Grau‐Rivera, O., Sala‐Vila, A., Sánchez‐Benavides, G., Arenaza‐Urquijo, E. M., Crous‐Bou, M., González‐de‐Echávarri, J. M., et al. (2020) · Alzheimer's & Dementia · doi:10.1002/alz.12131 · Cited by 241 · cited 1×
“However, an association was observed between CSF GFAP and Aβ pathology in CU individuals, as assessed by PET and CSF biomarkers (62, 63).”
BackgroundEscribano, L., Simón, A.-M., Gimeno, E., Cuadrado-Tejedor, M., López de Maturana, R., García-Osta, A., Ricobaraza, A., Pérez-Mediavilla, A., Del Río, J., & Frechilla, D. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.32 · Cited by 235
Microglia and Neuroinflammation: What Place for P2RY12?
Gómez Morillas, A., Besson, V. C., & Lerouet, D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041636 · Cited by 214 · cited 1×
“P2Y12R is a cell-surface protein expressed by microglia in the brain, its expression in other brain cells remains unclear (127).”
BackgroundAmyloid precursor protein metabolism and inflammation markers in preclinical Alzheimer disease
Alcolea, D., Martínez-Lage, P., Sánchez-Juan, P., Olazarán, J., Antúnez, C., Izagirre, A., Ecay-Torres, M., Estanga, A., Clerigué, M., Guisasola, M. C., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001859 · Cited by 163
The P2X7 Receptor: Central Hub of Brain Diseases
Andrejew, R., Oliveira-Giacomelli, Á., Ribeiro, D. E., Glaser, T., Arnaud-Sampaio, V. F., Lameu, C., & Ulrich, H. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.00124 · Cited by 162 · cited 1×
“Similarly, P2X7R is expressed in microglial cells, oligodendrocytes and Schwann cells (128).”
BackgroundIshiki, A., Kamada, M., Kawamura, Y., Terao, C., Shimoda, F., Tomita, N., Arai, H., & Furukawa, K. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13399 · Cited by 156
Omega-3 fatty acids' supplementation in Alzheimer's disease: A systematic review
Canhada, S., Castro, K., Perry, I. S., & Luft, V. C. (2018) · Nutritional Neuroscience · doi:10.1080/1028415x.2017.1321813 · Cited by 156
Mizrahi, R., Rusjan, P. M., Kennedy, J., Pollock, B., Mulsant, B., Suridjan, I., De Luca, V., Wilson, A. A., & Houle, S. (2012) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2012.46 · Cited by 155 · cited 1×
“A new generation of TSPO radiotracers has been recently developed aiming to avoid the need of genetic testing (116).”
BackgroundYasuno, F., Kosaka, J., Ota, M., Higuchi, M., Ito, H., Fujimura, Y., Nozaki, S., Takahashi, S., Mizukami, K., Asada, T., et al. (2012) · Psychiatry Research: Neuroimaging · doi:10.1016/j.pscychresns.2011.08.013 · Cited by 148 · cited 1×
“However, it was unable to predict the clinical outcome in terms of the type of dementia due to similar patterns of [11C]DAA1106 uptake in AD and Lewy body dementia converters (113).”
ResultKester, M. I., Teunissen, C. E., Sutphen, C., Herries, E. M., Ladenson, J. H., Xiong, C., Scheltens, P., van der Flier, W. M., Morris, J. C., Holtzman, D. M., et al. (2015) · Alzheimer's Research & Therapy · doi:10.1186/s13195-015-0142-1 · Cited by 146 · cited 2×
“Through numerous studies, CSF YKL-40 levels are increased in MCI and AD (80-82), but its role in AD pathophysiology is still poorly understood.”
BackgroundChronic TREM2 activation exacerbates Aβ-associated tau seeding and spreading
Jain, N., Lewis, C. A., Ulrich, J. D., & Holtzman, D. M. (2023) · Journal of Experimental Medicine · doi:10.1084/jem.20220654 · Cited by 146
Incretin and insulin signaling as novel therapeutic targets for Alzheimer’s and Parkinson’s disease
Nowell, J., Blunt, E., & Edison, P. (2023) · Molecular Psychiatry · doi:10.1038/s41380-022-01792-4 · Cited by 136
Fan, Z., Okello, A. A., Brooks, D. J., & Edison, P. (2015) · Brain · doi:10.1093/brain/awv288 · Cited by 135 · cited 2×
“Fan et al. (2015) (111) observed a persistent increase in the TSPO density at NEUROINFLAMMATION BIOMARKERS IN THE AT(N) FRAMEWORK ACROSS THE ALZHEIMER’S DISEASE CONTINUUM different stages of the disease in a 17-month longitudinal study.”
BackgroundEwers, M., Biechele, G., Suárez‐Calvet, M., Sacher, C., Blume, T., Morenas‐Rodriguez, E., Deming, Y., Piccio, L., Cruchaga, C., Kleinberger, G., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.202012308 · Cited by 133
Astrocyte Biomarkers in Alzheimer Disease: A Systematic Review and Meta-analysis
Bellaver, B., Ferrari-Souza, J. P., Uglione da Ros, L., Carter, S. F., Rodriguez-Vieitez, E., Nordberg, A., Pellerin, L., Rosa-Neto, P., Leffa, D. T., & Zimmer, E. R. (2021) · Neurology · doi:10.1212/wnl.0000000000012109 · Cited by 123
Self-citationINTREPAD: A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease
Meyer, P.-F., Tremblay-Mercier, J., Leoutsakos, J., Madjar, C., Lafaille-Maignan, M.-É., Savard, M., Rosa-Neto, P., Poirier, J., Etienne, P., Breitner, J., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000007232 · Cited by 113
Self-citationEmerging cerebrospinal fluid biomarkers in autosomal dominant Alzheimer's disease
Schindler, S. E., Li, Y., Todd, K. W., Herries, E. M., Henson, R. L., Gray, J. D., Wang, G., Graham, D. L., Shaw, L. M., Trojanowski, J. Q., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.12.019 · Cited by 101
Alzheimer’s Disease and Inflammaging
Kosyreva, A., Sentyabreva, A., Tsvetkov, I., & Makarova, O. (2022) · Brain Sciences · doi:10.3390/brainsci12091237 · Cited by 98
Femminella, G. D., Ninan, S., Atkinson, R., Fan, Z., Brooks, D. J., & Edison, P. (2016) · Journal of Alzheimer’s Disease · doi:10.3233/jad-150827 · Cited by 88 · cited 1×
“The [11C](R)PK11195-PET, the first TSPO tracer, presents high binding in AD-related brain regions such as frontal, temporal, parietal, and occipital cortices and hippocampus in dementia stages (110).”
BackgroundGalea, E., Weinstock, L. D., Larramona-Arcas, R., Pybus, A. F., Giménez-Llort, L., Escartin, C., & Wood, L. B. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105655 · Cited by 83
Glia-Driven Neuroinflammation and Systemic Inflammation in Alzheimer’s Disease
Hashioka, S., Wu, Z., & Klegeris, A. (2021) · Current Neuropharmacology · doi:10.2174/1570159x18666201111104509 · Cited by 78
Microglial Activation and Connectivity in Alzheimer Disease and Aging
Rauchmann, B., Brendel, M., Franzmeier, N., Trappmann, L., Zaganjori, M., Ersoezlue, E., Morenas‐Rodriguez, E., Guersel, S., Burow, L., Kurz, C., et al. (2022) · Annals of Neurology · doi:10.1002/ana.26465 · Cited by 61 · cited 2×
“While some studies observed increased significant differences between cognitively unimpaired (CU) and AD dementia individuals’ (40, 41) other reports found no alterations (42-48).”
BackgroundResultLivingston, N. R., Calsolaro, V., Hinz, R., Nowell, J., Raza, S., Gentleman, S., Tyacke, R. J., Myers, J., Venkataraman, A. V., Perneczky, R., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01429-y · Cited by 44 · cited 1×
“[11C]BU99008-PET studies in MCI and AD patients have identified a similar outcome to DED with an elevation on [11C]BU99008 uptake in Aβ-positive individuals; particularly, this elevation was superior in MCI than AD patients (158, 159).”
ResultSalvadó, G., Milà-Alomà, M., Shekari, M., Ashton, N. J., Operto, G., Falcon, C., Cacciaglia, R., Minguillon, C., Fauria, K., Niñerola-Baizán, A., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05897-4 · Cited by 36
TREM2 expression in the brain and biological fluids in prion diseases
Diaz-Lucena, D., Kruse, N., Thüne, K., Schmitz, M., Villar-Piqué, A., da Cunha, J. E. G., Hermann, P., López-Pérez, Ó., Andrés-Benito, P., Ladogana, A., et al. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02296-1 · Cited by 32
Clozapine induces astrocyte-dependent FDG-PET hypometabolism
Rocha, A., Bellaver, B., Souza, D. G., Schu, G., Fontana, I. C., Venturin, G. T., Greggio, S., Fontella, F. U., Schiavenin, M. L., Machado, L. S., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05682-3 · Cited by 31
Self-citationZimmer, E. R., Pascoal, T. A., Rosa-Neto, P., Nordberg, A., & Pellerin, L. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abm8302 · Cited by 17 · cited 1×
“For instance, [18F]FDG-PET is sensitive to activation/deactivation of astrocytes and microglial cells (171-175).”
MethodSelf-citationDe Kort, A. M., Kuiperij, H. B., Alcolea, D., Kersten, I., Versleijen, A. A. M., Greenberg, S. M., Stoops, E., Schreuder, F. H. B. M., Klijn, C. J. M., Lleó, A., et al. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-021-00899-0 · Cited by 13 · cited 1×
“Through numerous studies, CSF YKL-40 levels are increased in MCI and AD (80-82), but its role in AD pathophysiology is still poorly understood.”
Background
Cited by
Cummings, J. L., Atri, A., Feldman, H. H., Hansson, O., Sano, M., Knop, F. K., Johannsen, P., León, T., & Scheltens, P. (2025) · Alzheimer's Research & Therapy · doi:10.1186/s13195-024-01666-7 · Cited by 168
Cummings, J. L., Atri, A., Sano, M., Zetterberg, H., Scheltens, P., Knop, F. K., Johannsen, P., Wichmann, C. A., Abschneider, R. M., Leon, T., et al. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00459-9 · Cited by 110
Lista, S., Imbimbo, B. P., Grasso, M., Fidilio, A., Emanuele, E., Minoretti, P., López-Ortiz, S., Martín-Hernández, J., Gabelle, A., Caruso, G., et al. (2024) · Journal of Neuroinflammation · doi:10.1186/s12974-024-03163-y · Cited by 81
Boerwinkle, A. H., Wisch, J. K., Handen, B. L., Head, E., Mapstone, M., Rafii, M. S., O'Bryant, S. E., Krinsky‐McHale, S. J., Lai, F., Rosas, H. D., et al. (2025) · Alzheimer's & Dementia · doi:10.1002/alz.14359 · Cited by 14
Metadata
- Authors
- Bieger, A., Rocha, A., Bellaver, B., Machado, L., Da Ros, L., Borelli, W. V., Therriault, J., Macedo, A. C., Pascoal, T. A., Gauthier, S., Rosa-Neto, P., & Zimmer, E. R.
- Venue
- The Journal of Prevention of Alzheimer's Disease
- Publisher
- Elsevier BV
- Published
- 2023-09
- Volume
- 10
- Issue
- 3
- Pages
- 401-417
- ISSN
- 2274-5807 (ISSN-L)
- OpenAlex
- W4367335589
- Cited by
- 29
- References
- 69
- FWCI
- 2.40
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.